CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

On September 28, 2022 the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, a CD70-targeting CAR T-cell therapy, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS), which are are primary cutaneous T-cell lymphomas. There are two trials underway focusing on CTX130: COBALT-LYM for relapsed/refractory T or B cell malignancies and COBALT-RCC for relapsed/refractory renal cell carcinoma.